Investors

Announcements

2022

Further re Subscription

25 May 2021

Subscription

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused in the spinal (vertebral) stabilisation market, is pleased to announce that, further to the announcements of 1 April 2021 and 7 April 2021, it has raised an additional £78,000 through the subscription of 780,000 new ordinary shares ("Subscription Shares") at a price of £0.10 per share (the "Subscription Price" or the "Subscription").  Each Subscription Shares has a warrant attached exercisable at £0.15 per share (the "Warrant") for a period of three years from the date of admission of the Subscription Shares to trading on AQSE.

The Subscription was carried out on the same terms as the subscription notified on 1 April 2021 and 7 April 2021.

The total proceeds from this capital raise therefore amount to £698,500.

 

Admission of Subscription Shares

The Subscription is conditional on Admission and application will be made for the 780,000 Subscription Shares which will rank pari passu with the existing ordinary shares, to be admitted to trading on AQSE ("Admission").  It is expected that Admission will become effective and dealings in the Subscription Shares will commence on 28 May 2021.

 

Total Voting Rights

Following Admission, the Company's issued share capital will consist of 94,763,967 ordinary shares with voting rights. The new ordinary shares will rank pari passu with the existing ordinary shares. No ordinary shares are held in treasury at the date of this announcement and therefore following the Admission, the total number of Ordinary Shares in the Company with voting rights will be 94,763,967.

The above total voting rights figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

Special note concerning the Market Abuse Regulation:

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 ("MAR").  Market soundings, as defined in MAR, were taken in respect of the Subscription, with the result that certain persons became aware of inside information, as permitted by MAR.  That inside information is set out in this announcement.  Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

 

Enquiries:

Truspine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO




Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti




WH Ireland (Broker)

Tel: +44 (0)20 7220 1666

Adam Pollock




Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]

    

2021

Further re Subscription

25 May 2021

Subscription

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused in the spinal (vertebral) stabilisation market, is pleased to announce that, further to the announcements of 1 April 2021 and 7 April 2021, it has raised an additional £78,000 through the subscription of 780,000 new ordinary shares ("Subscription Shares") at a price of £0.10 per share (the "Subscription Price" or the "Subscription").  Each Subscription Shares has a warrant attached exercisable at £0.15 per share (the "Warrant") for a period of three years from the date of admission of the Subscription Shares to trading on AQSE.

The Subscription was carried out on the same terms as the subscription notified on 1 April 2021 and 7 April 2021.

The total proceeds from this capital raise therefore amount to £698,500.

 

Admission of Subscription Shares

The Subscription is conditional on Admission and application will be made for the 780,000 Subscription Shares which will rank pari passu with the existing ordinary shares, to be admitted to trading on AQSE ("Admission").  It is expected that Admission will become effective and dealings in the Subscription Shares will commence on 28 May 2021.

 

Total Voting Rights

Following Admission, the Company's issued share capital will consist of 94,763,967 ordinary shares with voting rights. The new ordinary shares will rank pari passu with the existing ordinary shares. No ordinary shares are held in treasury at the date of this announcement and therefore following the Admission, the total number of Ordinary Shares in the Company with voting rights will be 94,763,967.

The above total voting rights figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

Special note concerning the Market Abuse Regulation:

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 ("MAR").  Market soundings, as defined in MAR, were taken in respect of the Subscription, with the result that certain persons became aware of inside information, as permitted by MAR.  That inside information is set out in this announcement.  Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

 

Enquiries:

Truspine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO




Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti




WH Ireland (Broker)

Tel: +44 (0)20 7220 1666

Adam Pollock




Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]

    

2020

Further re Subscription

25 May 2021

Subscription

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused in the spinal (vertebral) stabilisation market, is pleased to announce that, further to the announcements of 1 April 2021 and 7 April 2021, it has raised an additional £78,000 through the subscription of 780,000 new ordinary shares ("Subscription Shares") at a price of £0.10 per share (the "Subscription Price" or the "Subscription").  Each Subscription Shares has a warrant attached exercisable at £0.15 per share (the "Warrant") for a period of three years from the date of admission of the Subscription Shares to trading on AQSE.

The Subscription was carried out on the same terms as the subscription notified on 1 April 2021 and 7 April 2021.

The total proceeds from this capital raise therefore amount to £698,500.

 

Admission of Subscription Shares

The Subscription is conditional on Admission and application will be made for the 780,000 Subscription Shares which will rank pari passu with the existing ordinary shares, to be admitted to trading on AQSE ("Admission").  It is expected that Admission will become effective and dealings in the Subscription Shares will commence on 28 May 2021.

 

Total Voting Rights

Following Admission, the Company's issued share capital will consist of 94,763,967 ordinary shares with voting rights. The new ordinary shares will rank pari passu with the existing ordinary shares. No ordinary shares are held in treasury at the date of this announcement and therefore following the Admission, the total number of Ordinary Shares in the Company with voting rights will be 94,763,967.

The above total voting rights figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

Special note concerning the Market Abuse Regulation:

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 ("MAR").  Market soundings, as defined in MAR, were taken in respect of the Subscription, with the result that certain persons became aware of inside information, as permitted by MAR.  That inside information is set out in this announcement.  Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

 

Enquiries:

Truspine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO




Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti




WH Ireland (Broker)

Tel: +44 (0)20 7220 1666

Adam Pollock




Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]